Researchers at the Icahn School of Medicine at Mount Sinai and collaborators have identified a previously overlooked protein, ...

Interstitial lung abnormalities (ILAs) are parenchymal lung changes found on high-resolution CT. In routine use of high-resolution CT, non-specific findings are frequently reported, which has prompted ...

The analysis reveals a strong dominance of AI applications in oncology, comprising 72.8% of all included studies. This skew ...

GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease ...

Insilico Medicine announces Nature Medicine publication of Phase IIa results evaluating rentosertib, the novel TNIK inhibitor for idiopathic pulmonary fibrosis (IPF) discovered and designed with a ...

Role of pirfenidone in the primary prophylaxis of lung cancer in idiopathic pulmonary fibrosis patients: A systematic review and meta-analysis.. If you have the appropriate software installed, you can ...

The trials were conducted with idiopathic pulmonary fibrosis patients or IPF (FIBRONEER-IPF study), and in secondary progressive pulmonary fibrosis (FIBRONEER-ILD study).

PureTech presented results of an open-label extension study of itsidiopathic pulmonary fibrosis candidate deupirfenidone, showing its durability.

About Idiopathic Pulmonary Fibrosis (IPF) Idiopathic Pulmonary Fibrosis (IPF) is a rare, progressive and fatal lung disease characterized by irreversible scarring of lung tissue.

• Periostin (POSTN) is a valuable idiopathic pulmonary fibrosis (IPF) serum biomarker with better diagnostic performance than Krebs von den Lungen-6 (KL-6), surfactant protein A (SP-A), and ...

Novotech, a globally recognized CRO has released an in-depth report on the global clinical trial landscape for Idiopathic Pulmonary Fibrosis.

Learn about idiopathic pulmonary fibrosis, its symptoms, diagnosis, and treatment options for managing this lung disease.